Adrenal insufficiency influences the pattern of thyrotoxicosis toward triiodothyronine predominance Authors: Azusa Maruoka, Kumiko Nishimura, Chika Mukai, Kazuhisa Takahashi, Junichiro Irie, Nagaoki Toyoda Published: 2026 ABSTRACT AbstractSerum-free thyroxine (FT4) levels are typically higher than free triiodothyronine (FT3) levels at the onset of thyrotoxicosis in patients with painless thyroiditis, reflecting the high ratio of stored thyroid hormone in the thyroid gland. We report a case of a 58-year-old man with painless thyroiditis and adrenal insufficiency caused by isolated adrenocorticotropin (ACTH) deficiency (IAD). Upon admission, the FT3 level was high, while the FT4 level was within the normal range. Likewise, the FT3/FT4 ratio was high. Therefore, the diagnosis of triiodothyronine (T3) thyrotoxicosis was made. He was diagnosed with painless thyroiditis because he did not have neck pain, and 99mTechnetium-thyroid scintigraphy revealed low thyroid uptake. The FT3/FT4 ratio fell after the increased serum cortisol level via daily administration of tetracosactide acetate. The elevated FT3/FT4 ratio in this patient could be explained by increased T4 to T3 conversion in a low-cortisol state. It has been suggested that destructive thyroiditis, accompanied by a high FT3/FT4 ratio, is a valuable indicator of the accompaniment of adrenal deficiency.Keywords: T3 thyrotoxicosis, painless thyroiditis, isolated ACTH deficiency Introduction Painless thyroiditis causes destruction-induced thyrotoxicosis. During the thyrotoxic phase, serum thyrotropin (TSH) levels are suppressed, and free thyroxine (FT4) and free triiodothyronine (FT3) levels are elevated. Typically, the serum FT4 levels are higher than the FT3 levels in painless thyroiditis [1-3]. In contrast, isolated adrenocorticotropin (ACTH) deficiency (IAD) is a pituitary disorder characterized by secondary adrenal insufficiency with low or absent cortisol production but normal secretion of pituitary hormones other than ACTH [4]. Although IAD is often associated with Hashimoto thyroiditis, its association with painless thyroiditis is rare [5, 6]. Serum T3 levels are reported to be higher during a low-cortisol state than during a normal-cortisol state in patients with chronic secondary adrenocortical insufficiency, whereas serum T4 levels are lower during the same period [7]. Here, we report the case of a patient with IAD and painless thyroiditis. Interestingly, the patient's serum FT3 level was high, whereas his serum FT4 level was within the normal range. A possible mechanism of triiodothyronine (T3) thyrotoxicosis in this patient is discussed. Case presentation A 58-year-old male patient was admitted to our hospital in April 2020 with appetite loss. He had been in good health until 3 months prior, working as a master carpenter, but then lost 14 kg. Family and other medical histories were non-contributory. On admission, the patient was thin, 168 cm tall, and weighed 51 kg (body mass index 18.1 kg/m2). His body temperature was 36.4°C, blood pressure was 117/73 mmHg, and pulse rate was 89/min. Clinical signs of anemia were noted upon physical examination; however, no jaundice, edema, or axillary or pubic hair loss were observed. No goiter was palpable. The Achilles reflex was normal. No tremors or lid lags were observed. Laboratory findings revealed normochromic, normocytic anemia and slight eosinophilia (Table 1). High serum calcium and phosphorus levels were also observed, although alkaline phosphatase levels were within the normal range and intact parathyroid hormone (PTH) levels were low (Table 1). Although TSH was suppressed, FT3 was elevated, and FT4 was within normal limits (Table 1). Therefore, the diagnosis of T3 thyrotoxicosis was made. Because the patient's appetite and weight loss were remarkable and he had slight eosinophilia, adrenal insufficiency was suspected. Serum cortisol and plasma ACTH were low (Table 1). Table 1Laboratory data on admissionTestResultReference range Hematology White blood cell count7100/μL3500-8500/μL Neutrophils35.3%42-77% Lymphocytes48.2%18-49% Eosinophils6.9%0.5-6.0% Basophils0.3%0.1-2.0%Red blood cell count421 × 104/μL400-570 × 104/μLHemoglobin12.3 g/dL (123 g/L)12.9-17.2 g/dL (129-172 g/L)Hematocrit36.8%38.2-50.8%Platelets22.6 × 104/μL14-34 × 104/μL Biochemistry Glucose98 mg/dL (5.44 nmol/L)80-112 mg/dL (4.4-6.2 nmol/L)Sodium139 mEq/L (139 mmol/L)138-146 mEq/L (138-146 mmol/L)Potassium4.0 mEq/L (4.0 mmol/L)3.5-5.0 mEq/L (3.5-5.0 mmol/L)Calcium11.5 mg/dL (2.88 nmol/L)8.5-10.3 mg/dL (2.13-2.58 nmol/L)Inorganic phosphate6.0 mg/dL (1.93 mmol/L)2.5-4.5 mg/dL (0.81-1.45 mmol/L)Alkaline phosphatase156 U/L (2.61 μkat/L)107-340 U/L (1.79-5.68 μkat/L)C-reactive protein0.22 mg/dL (2.2 mg/L)0-0.3 mg/dL (0-3.0 mg/L) Endocrinology FT41.48 ng/dL (19.20 pmol/L)0.7-1.48 ng/dL (9.08-19.2 pmol/L)FT37.62 pg/mL (11.70 pmol/L)1.71-3.71 pg/mL (2.63-5.70 pmol/L)TSH≦0.01 μIU/mL (≦0.01 mIU/L)0.35-4.94 μIU/mL (0.35-4.94 mIU/L)anti-TPOAb<1.0 IU/mL<5.61 IU/mLanti-TgAb15.39 IU/mL<4.11 IU/mLSerum cortisol≦0.5 μg/dL (≦13.8 nmol/L)7.1-19.6 μg/dL (195.9-540.8 nmol/L)Plasma ACTH<1.5 pg/mL (<0.33 pmol/L)7.2-63.3 pg/mL (1.60-14.03 pmol/L)Intact PTH7.8 pg/mL (0.83 pmol/L)18.4-80.1 pg/mL (1.95-8.50 pmol/L)FT4, free thyroxine; FT3, free triiodothyronine; TSH, thyrotropin; anti-TPOAb, anti-thyroid peroxidase antibody; anti-TgAb, anti-thyroglobulin antibody; ACTH, adrenocorticotropin; Intact PTH, Intact parathyroid hormone. Laboratory data on admission FT4, free thyroxine; FT3, free triiodothyronine; TSH, thyrotropin; anti-TPOAb, anti-thyroid peroxidase antibody; anti-TgAb, anti-thyroglobulin antibody; ACTH, adrenocorticotropin; Intact PTH, Intact parathyroid hormone. Diagnostic assessment The patient tested positive for anti-thyroglobulin antibodies (anti-TgAb). Thyroid echography showed a slightly diffusely enlarged thyroid with uniform echogenicity. 99mTechnetium-thyroid scintigraphy showed low thyroid uptake (0.3%, reference range 0.5-4%) (Fig. 1). Based on these findings, the patient was diagnosed with painless thyroiditis and was closely followed up without medication. 99mTechnetium-thyroid scintigraphy showed low thyroid uptake. Serum cortisol responded only slightly after bolus injection of 0.25 mg ACTH; however, 3 days of daily tetracosactide acetate (0.5 mg) injections increased serum cortisol (Fig. 2). Corticotropin-releasing hormone did not increase plasma ACTH concentration. Thyrotropin-releasing hormone (TRH) increased prolactin levels. Both luteinizing and follicle-stimulating hormone levels were increased by the infusion of luteinizing hormone-releasing hormone. The response to growth hormone-releasing peptide-2 was also normal. These results are compatible with secondary adrenocortical insufficiency due to IAD. Pituitary magnetic resonance imaging showed no remarkable abnormalities. Clinical course. The figure shows changes in serum concentrations of FT4 (ng/dL, green line, reference 0.7-1.48 ng/dL [9.08-19.2 pmol/L]), FT3 (pg/mL, yellow line, reference 1.71-3.71 pg/mL [2.63-5.70 pmol/L]), TSH (μIU/mL, blue line, reference 0.35-4.94 μIU/mL [0.35-4.94 mIU/L]), cortisol (μg/dL), and the ratio of FT3 to FT4 (pg/mL per ng/dL, red line) from the date of admission (Day 0). The green area in the graph represents the normal reference range of FT4, and the yellow area represents the normal reference range of FT3. FT4, free thyroxine; FT3, free triiodothyronine; TSH, thyrotropin; FT3/FT4, ratio of free triiodothyronine to free thyroxine. Based on the high serum calcium and phosphorus, normal alkaline phosphatase, and low intact PTH levels, increased bone resorption related to hyperthyroidism was considered. Treatment After the diagnosis of adrenal insufficiency, the patient was started on hydrocortisone (10 mg/day) on Day 8 after admission, followed by tetracosactide acetate (0.5 mg/day) for 3 consecutive days from Day 13 to Day 15 to distinguish primary adrenal insufficiency from IAD; the dosage of hydrocortisone was increased to 15 mg/day from Day 16 (Fig. 2). Outcome and follow-up FT3 fell from 7.62 to 2.92 pg/mL (11.70-4.48 pmol/L) and the FT3/FT4 ratio decreased from 5.15 to 3.07 pg/mL per ng/dL (0.61-0.36 pmol/L per pmol/L) on Day 16 after admission (Fig. 2). FT3, FT4, and TSH levels were 3.04 pg/mL (4.67 pmol/L), 1.00 ng/dL (12.97 pmol/L), and 1.246 μIU/mL (1.246 mIU/L), respectively, on Day 177 (Fig. 2). Discussion We encountered a patient with painless thyroiditis and IAD who presented with T3 thyrotoxicosis. Typically, serum FT4 levels are higher than FT3 levels in painless thyroiditis [1-3] because the molar ratio of stored T4 to T3 in the human thyroid gland is estimated to be 15:1 [8]. Therefore, T3 thyrotoxicosis was a distinguishing feature of our patient with painless thyroiditis. In the present case, only anti-TgAb levels were mildly elevated, whereas anti-thyroid peroxidase antibodies (anti-TPOAb) were negative. Painless thyroiditis developed after an adrenalectomy in patients with Cushing syndrome [9] or after rapid progression of secondary adrenal insufficiency following pituitary apoplexy [10] or concurrently with Addison disease [11]. A reduction in serum glucocorticoid levels makes patients more susceptible to autoimmune diseases because glucocorticoids play an important modulatory role in the immune system [12]. Thus, it is possible that the alteration of the immune system induced by adrenal insufficiency triggers the development of painless thyroiditis. Patients with Cushing syndrome have reduced serum T3 and low TSH levels [13]. Furthermore, pharmacological doses of glucocorticoids have been reported to reduce the peripheral conversion of T4 to T3 [14]. In contrast, it was reported that serum T3 levels were higher and serum T4 levels were lower during a low-cortisol state than during a normal-cortisol state in patients with chronic secondary adrenocortical insufficiency; the serum T4 level was lower during the same period [7]. Therefore, the T3/T4 ratio in the low-cortisol state was significantly higher than that in the normal-cortisol state in those patients [7]. In contrast, serum 3,3′,5′-triiodothyronine (rT3) levels decreased during a low-cortisol state in these patients. The simultaneous decrease in rT3 during the increase in T3 strongly suggests that the increase in T3 may be, at least in part, due to an increase in the peripheral conversion of T4 to T3 during cortisol deficiency, in contrast to what has been described during glucocorticoid excess [15]. Serum TSH levels are similar in both normal- and low-cortisol states in these patients [7]. Patients with painless thyroiditis associated with IAD have been previously reported [6]. Thyrotoxicosis due to painless thyroiditis likely aggravates the symptoms of insidious adrenal insufficiency in patients with IAD. Thyrotoxicosis accelerates the disposal of endogenous or exogenous cortisol by increasing hepatic Δ4,5-steroid reductase activity [16]. Approximately 80% of the circulating T3 in humans is produced by the 5′-deiodination of T4 outside the thyroid gland. The quantitative contribution of different tissues in the body to the total production of T3 from T4 is unknown, but it is known that type 1 and type 2 iodothyronine deiodinase catalyze this reaction [17]. When T4 is released from the thyroid due to tissue destruction, it is promptly converted to T3 via increased 5′-deiodination during cortisol deficiency. Subsequently, the serum FT3 level increased, and the serum FT4 level decreased to normal. The degree of glucocorticoid deficiency may also be a contributing factor in the serum FT3 level in patients with painless thyroiditis associated with IAD, as 5′-deiodination of T4 is regulated by serum cortisol level. The common clinical manifestations of IAD and painless thyroiditis include general fatigue, appetite loss, nausea, and vomiting [6]. Obtaining a correct diagnosis of IAD and painless thyroiditis can take time, as these clinical manifestations are non-specific and may be subtle. Since cortisol deficiency is potentially life-threatening, early diagnosis is important. We suggest that destructive thyroiditis accompanied by a high FT3/FT4 ratio is a valuable indicator of the accompaniment of adrenal deficiency. Learning points Typically, serum FT4 levels are higher than FT3 levels in painless thyroiditis. Typically, serum FT4 levels are higher than FT3 levels in painless thyroiditis. Patients with painless thyroiditis rarely have IAD. Patients with painless thyroiditis rarely have IAD. FT3/FT4 ratio is increased in patients with a low-cortisol state. FT3/FT4 ratio is increased in patients with a low-cortisol state. In patients with symptoms suggestive of adrenal insufficiency, cortisol deficiency may influence the pattern of thyrotoxicosis, favoring T3 predominance, warranting further evaluation. In patients with symptoms suggestive of adrenal insufficiency, cortisol deficiency may influence the pattern of thyrotoxicosis, favoring T3 predominance, warranting further evaluation. Contributors All authors made individual contributions to authorship. A.M., C.M., K.N., K.T., J.I., and N.T. were involved in diagnosis and management of the patient. A.M. and N.T. were involved in writing and editing of the manuscript. All authors reviewed and approved the final draft. Contributor Information Azusa Maruoka, Internal Medicine II, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka 573-1010, Japan. Kumiko Nishimura, Internal Medicine II, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka 573-1010, Japan. Chika Mukai, Internal Medicine II, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka 573-1010, Japan. Kazuhisa Takahashi, Internal Medicine II, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka 573-1010, Japan. Junichiro Irie, Internal Medicine II, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka 573-1010, Japan. Nagaoki Toyoda, Internal Medicine II, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka 573-1010, Japan. Funding No public or commercial funding. Disclosures None of the authors have any potential conflicts of interest associated with this research. Informed patient consent for publication Signed informed consent was directly obtained from the patient. Data availability Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.